Devapamil
 | |
| Names | |
|---|---|
| IUPAC name (RS)-2-(3,4-dimethoxyphenyl)-2-isopropyl-5-[2-(3-methoxyphenyl)ethyl-methylamino]pentanenitrile | |
| Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
| ChEBI |
|
| ChEMBL |
|
| ChemSpider |
|
PubChem CID |
|
| UNII |
|
InChI
| |
| |
| Properties | |
Chemical formula | C26H36N2O3 |
| Molar mass | 424.57564 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references | |
Chemical compound
Devapamil is a calcium channel blocker. It is also known as desmethoxyverapamil, which is a phenylalkylamine (PAA) derivative.[1] Devapamil not only inhibits by blocking the calcium gated channels, but also by depolarizing the membrane during the sodium-potassium exchanges.[2]
Structure
Devapamil consists of two aromatic rings with methoxy substituents connected by an alkylamine chain increasing flexibility and overall potency.[3]
Animal studies
Devapamil in rats can be used to decrease glutathione levels and increase oxidation of lipids, which makes it effective in preclusion of ulcers caused by stress.[4][5] The medical characteristics of this drug, and other phenylalkylamines, depends greatly on the state of the calcium channels being targeted which results in a greater affinity and drug efficiency. [6]
References
- ^ Erdmann R, Lüttgau HC (June 1989). "The effect of the phenylalkylamine D888 (devapamil) on force and Ca2+ current in isolated frog skeletal muscle fibres". The Journal of Physiology. 413 (1): 521–41. doi:10.1113/jphysiol.1989.sp017667. PMC 1189114. PMID 2557440.
- ^ Dierkes PW, Wende V, Hochstrate P, Schlue WR (July 2004). "L-type Ca2+ channel antagonists block voltage-dependent Ca2+ channels in identified leech neurons". Brain Research. 1013 (2): 159–67. doi:10.1016/j.brainres.2004.03.038. PMID 15193524. S2CID 22004238.
- ^ Cheng RC, Tikhonov DB, Zhorov BS (October 2009). "Structural model for phenylalkylamine binding to L-type calcium channels". The Journal of Biological Chemistry. 284 (41): 28332–42. doi:10.1074/jbc.M109.027326. PMC 2788883. PMID 19700404.
- ^ Alican I, Toker F, Arbak S, Yegen BC, Yalçin AS, Oktay S (August 1994). "Gastric lipid peroxidation, glutathione and calcium channel blockers in the stress-induced ulcer model in rats". Pharmacological Research. 30 (2): 123–35. doi:10.1016/1043-6618(94)80004-9. PMID 7816741.
- ^ Hung CR (May 2004). "Protective effects of lysozyme chloride and reduced glutathione on betel quid chewing-produced gastric oxidative stress and haemorrhagic ulcer in rats". Inflammopharmacology. 12 (2): 115–29. doi:10.1163/1568560041352284. PMID 15265315. S2CID 860321.
- ^ Cheng RC, Tikhonov DB, Zhorov BS (October 2009). "Structural model for phenylalkylamine binding to L-type calcium channels". The Journal of Biological Chemistry. 284 (41): 28332–42. doi:10.1074/jbc.M109.027326. PMC 2788883. PMID 19700404.
- v
- t
- e
Ion channel modulators
| VGKCsTooltip Voltage-gated potassium channels |
| ||||
|---|---|---|---|---|---|
| IRKsTooltip Inwardly rectifying potassium channel |
| ||||
| KCaTooltip Calcium-activated potassium channel |
| ||||
| K2PsTooltip Tandem pore domain potassium channel |
|
| VGSCsTooltip Voltage-gated sodium channels |
| ||||
|---|---|---|---|---|---|
| ENaCTooltip Epithelial sodium channel |
| ||||
| ASICsTooltip Acid-sensing ion channel |
|
| CaCCsTooltip Calcium-activated chloride channel |
| ||||
|---|---|---|---|---|---|
| CFTRTooltip Cystic fibrosis transmembrane conductance regulator |
| ||||
| Unsorted |
|
| TRPsTooltip Transient receptor potential channels |
|
|---|---|
| LGICsTooltip Ligand gated ion channels |
|
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
 | This biochemistry article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
